novo nordisk semaglutide mash GLP-1 Drug Meets Goals of Trial, Setting Stage for FDA & EMA Filings Novo Nordisk leads MASH therapeutic

Retatrutide is still under clinical development, and while early research has shown promising results for weight management, some potential side effects have been observed in studies

Less conventional treatments include nutritional supplementation such as selenium or iodine and botanicals such as bugleweed and motherwort which can regulate thyroid function and alleviate symptoms without a lifetime of prescription medications

Semaglutide reduces appetite, slows gastric emptying, and increases feelings of fullness, offering a novel approach to weight management by influencing appetite and metabolism

Pregnant or nursing individuals should consult providers before starting any glutathione supplementation protocol

Not mandatory, but highly recommended